If there's a silver lining to the COVID-19 pandemic, it's how the world came together to find a solution as one. Throughout the pandemic, technology has enabled global collaboration, as more people shifted to working from home, while science allowed multiple COVID-19 vaccines to be developed and rolled out in record time, despite working remotely. The convergence of governments and industries, particularly biopharmaceuticals, to innovate and create a solution to the crisis was inspiring, but it raises questions around what's needed to see this pace of innovation again. Do we need a global crisis to innovate? Or can biopharma companies forge their own pathways to innovate, while making solutions more affordable and accessible to those who are most affected: patients?